TIL therapy broadens the tumor-reactive CD8<sup>+</sup>T cell compartment in melanoma patients
Pia Kvistborg(The Netherlands Cancer Institute), Ton N. Schumacher(Leiden University Medical Center), Marit M. van Buuren(The Netherlands Cancer Institute), John B.A.G. Haanen(Leiden University Medical Center), Per thor Straten(Herlev Hospital), Mireille Toebes(The Netherlands Cancer Institute), Jacob Schachter, Manuel Fankhauser(Dutch Cancer Society), Sine Reker Hadrup(Herlev Hospital), Paul F. Robbins(National Cancer Institute), Jos Urbanus(Dutch Cancer Society), Bianca Heemskerk(The Netherlands Cancer Institute), Michal J. Besser(Tel Aviv University), Joost B. Beltman(Utrecht University), Steven A. Rosenberg(National Cancer Institute), Mark E. Dudley(National Cancer Institute), Nienke van Rooij(The Netherlands Cancer Institute), Chengyi J. Shu(Dutch Cancer Society), Charlotte Albæk Thrue(Herlev Hospital), Gemma G. Kenter(European Organisation for Research and Treatment of Cancer), Carsten Linnemann(The Netherlands Cancer Institute), Yong F. Li(National Institutes of Health)
Cited by 176
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
|Journal of Clinical Oncology|2008|1.3k
IL-2: The First Effective Immunotherapy for Human Cancer
|The Journal of Immunology|2014|1.3k